

GRIFOLS
SCIENTIFIC
AWARDS

ASPIRE

Award for Scientific Progress
in Immunodeficiency Research

GRIFOLS

ASPIRE

Award for Scientific Progress in Immunodeficiency Research

THE ASPIRE AWARD

The ASPIRE Award program is launched with the aim of identifying and supporting innovative clinical research projects that offer a greater insight into primary and secondary immunodeficiency diseases.

It provides financial **support to young scientists and clinicians who wish to undertake a research project that seeks to improve immunodeficiency awareness, diagnosis and immunoglobulin therapy.**

Grifols is proud of the ASPIRE Award program and believes it demonstrates the company's commitment to innovation in this field of scientific endeavor. Hopefully, the program will ultimately contribute to improving standards of care and delivering a brighter future for patients with immunodeficiency.

ABOUT THE ASPIRE PROGRAM

Grifols is a global biotherapeutic and biotechnology company that discovers, develops and produces treatments and services for patients.

The program is particularly focusing on innovative ideas in the field of immunoglobulin research in primary and secondary immunodeficiencies. Proposals may include, but are not limited to: efficacy, mechanism of action, safety and tolerability, quality of life, and pharmacoeconomics.

The ASPIRE Award Program offers €50,000 to the applicant whose proposal best matches the program's objectives, as assessed by an independent review committee.

The ASPIRE Award aims to:

- Improve immunodeficiency diseases awareness diagnostics and management
- Develop novel concepts on immunoglobulin therapy research

WHO CAN APPLY

Young scientists or clinicians with an innovative idea relevant to immunoglobulin research in primary and secondary immunodeficiencies. Applications are encouraged from both individuals and teams who may be conducting research at hospitals, universities or independent institutions.

Applicants must meet the following eligibility criteria to apply for the ASPIRE Award program:

- Applicants must present a focused project with goals that can be achieved within 24 months.
- Applicants must be employed or supported by an institution.
- Applicants must be under the age of 45 at the timepoint of letter of intent submission.

EVALUATIONS AND SELECTION OF RESEARCH PROPOSALS

Applications are evaluated based on four criteria:

- Scientific merit
- Innovation
- Clinical and medical impact
- Quality of research environment

The review board will be looking for significant contributions clinical research in the field of primary and secondary immunodeficiencies.

TIMELINES FOR THE ASPIRE AWARD PROGRAM

Open for submission:
October 16th, 2020

Deadline for participation:
March 31st, 2021

Publication of awardees' names on the Grifols website:
July, 2021

Additional information on the grant program, detailed timelines, the constitution of the review board, and the application process can be found on our website. For more detailed information on the ASPIRE Awards please visit:

<http://www.aspire-awards.grifols.com>



GRIFOLS SCIENTIFIC AWARDS



Martín Villar

Hemostasis Awards



Albus

Albumin Awards Program



SPIN

Scientific Progress
Immunoglobulins in Neurology



GATRA

Grifols Antithrombin
Research Awards



ALTA

Alpha-1-Antitrypsin
Laurell's Training Award



ASPIRE

Award for Scientific Progress
in Immunodeficiency Research

GRIFOLS